

# 해외 바이오의약품 임상 현황 (2020.06.29~2020.07.05)

한국바이오의약품협회, 2020.7.7.  
출처: ClinicalTrials.gov

## ○ 미국 107건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04432506	Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma	Hematopoietic and Lymphoid Cell Neoplasm Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleuce Drug: Cyclophosphamide Drug: Fludarabine	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1  Phase 2
NCT04423029	Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications	Solid Tumor Melanoma Renal Cell Carcinoma Urothelial Carcinoma	Biological: DF6002 Biological: Pembrolizumab	Dragonfly Therapeutics	Phase 1  Phase 2
NCT04407247	Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma	Colitis Lung Non-Small Cell Carcinoma Malignant Genitourinary System Neoplasm Malignant Solid Neoplasm Melanoma	Biological: Infliximab Biological: Vedolizumab	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1  Phase 2
NCT04386252	Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults	COVID-19	Biological: AV-COVID-19	Aivita Biomedical, Inc.	Phase 1  Phase 2
NCT04331067	Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer	Triple Negative Breast Cancer	Drug: Paclitaxel Drug: Carboplatin Biological: Nivolumab Biological: Cabiralizumab Procedure: Tumor biopsy Procedure: Bone marrow Procedure: Blood draw	Washington University School of Medicine Bristol-Myers Squibb	Phase 1  Phase 2
NCT04285671	Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer	Metastatic Lung Non-Small Cell Carcinoma Refractory Lung Non-Small Cell Carcinoma Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Biological: Necitumumab Drug: Osimertinib Other: Quality-of-Life Assessment Other: Questionnaire Administration Biological: Trastuzumab	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) Eli Lilly and Company Genentech, Inc.	Phase 1  Phase 2
NCT04263090	Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment	Non-small Cell Lung Cancer Adenocarcinoma Stage IV	Drug: Rigosertib Drug: Nivolumab	Icahn School of Medicine at Mount Sinai Bristol-Myers Squibb Onconova Therapeutics, Inc.	Phase 1  Phase 2
NCT03851081	Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia	Allogeneic Hematopoietic Stem Cell Transplantation Recipient Blasts 5 Percent or More of Bone Marrow Nucleated Cells Blasts 5 Percent or More of Peripheral Blood White Cells CD22 Positive Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells Lymphoblasts 20 Percent or More of Peripheral Blood White Cells Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia	Biological: Inotuzumab Ozogamicin Other: Quality-of-Life Assessment Drug: Vincristine Sulfate Liposome	Roswell Park Cancer Institute National Cancer Institute (NCI) Pfizer	Phase 1  Phase 2
NCT03597594	Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)	Severe Combined Immunodeficiency	Drug: Anti-thymocyte globulin (rabbit) Drug: Busulfan Drug: Fludarabine Drug: Thiotepa Device: ClineMACS Other: Donor Lymphocyte Infusion	St. Jude Children's Research Hospital	Phase 1  Phase 2
NCT03520751	Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A	Charcot-Marie-Tooth Neuropathy Type 1A	Drug: scAAV1.tMCK.NTF3	Nationwide Children's Hospital	Phase 1  Phase 2
NCT04384445	Organicell Flow for Patients With COVID-19	Corona Virus Infection COVID-19 SARS Acute Respiratory Distress Syndrome	Biological: Organicell Flow Other: Placebo	Organicell Regenerative Medicine	Phase 1  Phase 2
NCT04263831	LOW DOSE IL-2 FOR THE TREATMENT OF CROHN'S DISEASE	Crohn Disease	Drug: Interleukin-2 (aldesleukin).	Boston Children's Hospital	Phase 1  Phase 2
NCT04456413	Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection	COVID-19	Biological: Convalescent Plasma Other: Best Supportive Care	Hackensack Meridian Health	Phase 2
NCT04454489	Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition	Advanced Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Head-and-neck Squamous-cell Carcinoma	Drug: Pembrolizumab (immunotherapy) Radiation: Quad-shot palliative radiotherapy	Wake Forest University Health Sciences National Cancer Institute (NCI)	Phase 2
NCT04450173	Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma	Ann Arbor Stage II Follicular Lymphoma Ann Arbor Stage III Follicular Lymphoma Ann Arbor Stage IV Follicular Lymphoma Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma	Drug: Ibrutinib Biological: Obinutuzumab Drug: Venetoclax	Joseph Tuscano National Cancer Institute (NCI) Pharmacyclics LLC. Genentech, Inc. University of California, Davis	Phase 2
NCT04448886	Sacituzumab Govitecan Vs Pembrolizumab In HR+ / HER2 - MBC	Invasive Breast Cancer Metastatic Breast Cancer HR-Positive Breast Cancer HER2-negative Breast Cancer	Drug: Pembrolizumab Drug: Sacituzumab Govitecan	Sara Tolane Merck Sharp & Dohme Corp. Immunomedics, Inc. Dana-Farber Cancer Institute	Phase 2
NCT04447768	The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)	Chronic Lymphocytic Leukemia (CLL)	Drug: Obinutuzumab Drug: Venetoclax	Memorial Sloan Kettering Cancer Center Genentech, Inc.	Phase 2
NCT04447716	An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment	Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Follicular Lymphoma Recurrent Indolent Adult Non-Hodgkin Lymphoma Recurrent Marginal Zone Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Follicular Lymphoma Refractory Indolent Adult Non-Hodgkin Lymphoma Refractory Marginal Zone Lymphoma	Drug: Venetoclax Drug: Lenalidomide Biological: Rituximab Biological: Rituximab and Hyaluronidase Human	Thomas Jefferson University National Cancer Institute (NCI)	Phase 1
NCT04446117	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC	Metastatic Prostate Cancer Prostate Adenocarcinoma	Drug: Cabozantinib Drug: Atezolizumab Drug: Abiraterone Acetate Drug: Enzalutamide Drug: Prednisone	Exelixis Roche-Genentech Takeda	Phase 3
NCT04444622	Immunotherapy for Third Line Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	Biological: AlloStim	Immunovative Therapies, Ltd. Mirror Biologics, Inc.	Phase 2
NCT04434560	Neoadjuvant Immunotherapy in Brain Metastases	Brain Metastases, Adult	Drug: Nivolumab Drug: Ipilimumab	Sarah Sammons, MD Bristol-Myers Squibb Duke University	Phase 2

# 해외 바이오의약품 임상 현황 (2020.06.29~2020.07.05)

한국바이오의약품협회, 2020.7.7.  
출처: ClinicalTrials.gov

NCT04430699	Cisplatin+Pembrolizumab+RT in Vulvar Cancer	Vulvar Cancer Vulvar Squamous Cell Carcinoma	Drug: Cisplatin Drug: Pembrolizumab Radiation: Radiation Therapy	Massachusetts General Hospital Merck Sharp & Dohme Corp.	Phase 2
NCT04430452	Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition	Advanced Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v8 Stage IIIA Hepatocellular Carcinoma AJCC v8 Stage IIIB Hepatocellular Carcinoma AJCC v8 Stage IV Hepatocellular Carcinoma AJCC v8 Stage IVA Hepatocellular Carcinoma AJCC v8 Stage IVB Hepatocellular Carcinoma AJCC v8	Biological: Durvalumab Radiation: Hypofractionated Radiation Therapy Biological: Tremelimumab	Mary Feng, MD AstraZeneca University of California, San Francisco	Phase 2
NCT04420975	Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma	Leiomyosarcoma Myxofibrosarcoma Resectable Dedifferentiated Liposarcoma Resectable Soft Tissue Sarcoma Resectable Undifferentiated Pleomorphic Sarcoma Soft Tissue Fibrosarcoma Spindle Cell Sarcoma Stage I Retroperitoneal Sarcoma American Joint Committee on Cancer (AJCC) v8 Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Stage IA Retroperitoneal Sarcoma AJCC v8 Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Stage IB Retroperitoneal Sarcoma AJCC v8 Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Stage II Retroperitoneal Sarcoma AJCC v8 Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Storiform-Pleomorphic Malignant Fibrous Histiocytoma Synovial Sarcoma Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant	Procedure: Definitive Surgical Resection Drug: Immunotherapeutic Agent Biological: Nivolumab Radiation: Radiation Therapy	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04420221	Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 50 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)	Infections, Soft Tissue	Biological: Sa-5Ag half dose non-adjuvanted Biological: Sa-5Ag full dose non-adjuvanted Biological: Sa-5Ag half dose adjuvanted Biological: Sa-5Ag full dose adjuvanted Drug: Placebo	GlaxoSmithKline	Phase 1
NCT04419909	Retreatment With CTL019/CTL119	Lymphoma, B-Cell	Drug: CD19 redirected autologous T cells (CTL019 or CTL119 cells)	Abramson Cancer Center of the University of Pennsylvania	Phase 1
NCT04417361	Galcanezumab for Vestibular Migraine	Vestibular Migraine	Drug: Galcanezumab Prefilled Syringe Drug: Placebo	University of California, San Francisco Eli Lilly and Company	Phase 2
NCT04414540	Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients	Head and Neck Squamous Cell Carcinoma	Drug: Metformin Extended Release Oral Tablet Drug: Pembrolizumab	Trisha Wise-Draper American Cancer Society, Inc. University of Cincinnati	Phase 2
NCT04409600	Comparison of Non-Surgical Treatment Options for Chronic Exertional Compartment Syndrome (CECS)	Chronic Exertional Compartment Syndrome	Behavioral: Supervised Gait Retraining Behavioral: Home Based Gait Retraining Drug: Saline Injection Drug: Botulinum Toxin Injection	Walter Reed National Military Medical Center Uniformed Services University of the Health Sciences	Phase 2
NCT04409509	Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID???)	Coronavirus Disease 2019 (COVID???)	Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody Drug: Placebo	CSL Behring	Phase 2
NCT04404283	Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL	Diffuse Large B-cell Lymphoma	Drug: Brentuximab vedotin Drug: Rituximab Drug: Lenalidomide Other: Placebo	Seattle Genetics, Inc.	Phase 3
NCT04401995	Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab	Melanoma	Drug: CMP-001 Biological: Nivolumab Other: [18F]F-AraG PET/CT	Diwakar Davar Checkmate Pharmaceuticals CellSight Technologies, Inc. University of Pittsburgh	Phase 2
NCT04396496	Treatment of POEMS Syndrome With Daratumumab	POEMS Syndrome	Drug: Daratumumab Injection	University of Arkansas Janssen Scientific Affairs, LLC	Phase 2
NCT04391309	IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)	SARS-CoV2	Biological: IC14 Other: Placebo	Implicit Bioscience University of Washington	Phase 2
NCT04380740	Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis	Graft Vs Host Disease	Drug: Placebo Drug: Abatacept	Boston Children's Hospital Bristol-Myers Squibb	Phase 2
NCT04377932	Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors	Liver Cancer Rhabdomyosarcoma Malignant Rhabdoid Tumor Liposarcoma Wilms Tumor Yolk Sac Tumor	Genetic: AGAR T cells Drug: Cytosine Drug: Fludara	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1
NCT04373369	Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer	Extensive-stage Small Cell Lung Cancer	Drug: Vorolanib Drug: Atezolizumab	Washington University School of Medicine Xcovery Holding Company, LLC	Phase 2
NCT04370509	Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery	Metastatic Clear Cell Renal Cell Carcinoma Recurrent Clear Cell Renal Cell Carcinoma Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Clear Cell Renal Cell Carcinoma	Drug: Axitinib Procedure: Cytoreductive Nephrectomy (CN) Procedure: Metastasectomy (MET) Biological: Pembrolizumab	University of California, San Francisco Merck Sharp & Dohme Corp.	Phase 2
NCT04362839	Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	Advanced Colon Adenocarcinoma Metastatic Colon Adenocarcinoma Metastatic Colorectal Adenocarcinoma Metastatic Colorectal Carcinoma Metastatic Rectal Adenocarcinoma Stage III Colon Cancer AJCC v8 Stage III Rectal Cancer AJCC v8 Stage IIIA Colon Cancer AJCC v8 Stage IIIB Rectal Cancer AJCC v8 Stage IIIC Colon Cancer AJCC v8 Stage IIIC Rectal Cancer AJCC v8 Stage IV Colon Cancer AJCC v8 Stage IV Colorectal Cancer AJCC v8 Stage IV Rectal Cancer AJCC v8 Stage IVA Colon Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVA Rectal Cancer AJCC v8 Stage IVB Colon Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVB Rectal Cancer AJCC v8 Stage IVC Colon Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Stage IVC Rectal Cancer AJCC v8	Biological: Ipilimumab Biological: Nivolumab Drug: Regorafenib	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1

# 해외 바이오의약품 임상 현황 (2020.06.29~2020.07.05)

한국바이오의약품협회, 2020.7.7.  
출처: ClinicalTrials.gov

NCT04362501	Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)	Chronic Sinusitis	Biological: dupilumab Drug: placebo	Johns Hopkins University	Phase 2
NCT04357587	Safety and Feasibility of PD-1 Blockade in the Treatment of Rectal Cancer	Rectal Neoplasms	Drug: Pembrolizumab Radiation: External beam radiation Drug: Capecitabine	Case Comprehensive Cancer Center	Phase 1
NCT04331275	Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant	Solid Organ Transplant Viral Infection	Biological: Viral Specific T-cells (VSTs)	Children's Hospital Medical Center, Cincinnati Hoxworth Blood Center	Phase 2
NCT04323202	Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N	Basal Cell Carcinoma of the Head and Neck	Drug: Pembrolizumab Other: Tissue collection	Brian Gastman Case Comprehensive Cancer Center	Phase 1
NCT04312113	Angiographic Delivery of AD-MSC for Ulcerative Colitis	Ulcerative Colitis	Drug: Adipose derived, autologous mesenchymal stem cells	Mayo Clinic	Phase 1
NCT04301778	Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Unresectable Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: SNDX-6352	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals AstraZeneca	Phase 2
NCT04287985	Safety and Efficacy Study of VIS649 for IgA Nephropathy	Immunoglobulin A Nephropathy Glomerular Disease IgAN	Drug: Dose-Placebo Drug: Low Dose-VIS649 Drug: Medium Dose-VIS649 Drug: High Dose-VIS649	Visterra, Inc.	Phase 2
NCT04287920	Acamprostate Safe to Use in Individuals With Liver Disease.	Alcohol-related Liver Disease	Drug: Acomprostate	Mayo Clinic	Phase 2
NCT04280471	Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease	Acute Graft Versus Host Disease Gastrointestinal Tract Acute Graft Versus Host Disease Severe Gastrointestinal Tract Acute Graft Versus Host Disease Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease	Drug: Fecal Microbiota Transplantation Capsule	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04274452	A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)	Primary Immune Thrombocytopenia (ITP)	Biological: efgartigimod Other: Placebo	argenx BVBA	Phase 3
NCT04240808	Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)	Non Hodgkin Lymphoma	Biological: UCD19 CAR T Cells	University of Colorado, Denver	Phase 1
NCT04230031	Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab	Saad Z. Usmani, MD Janssen Research & Development, LLC Atrium Health	Phase 2
NCT04219163	Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen	Acute Myeloid Leukemia	Biological: CLL-1.CAR T cells	Baylor College of Medicine The Methodist Hospital System Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1
NCT04209686	Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma	Advanced Gastric Adenocarcinoma	Drug: Paclitaxel Drug: Olaparib Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Merck Sharp & Dohme Corp.	Phase 2
NCT04199767	SNIFF Multi-Device Study 2	Mild Cognitive Impairment Cognitive Impairment	Drug: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) Drug: 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)	Wake Forest University Health Sciences	Phase 2
NCT04177810	Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer	Metastatic Pancreatic Cancer	Drug: Cemiplimab Drug: Plerixafor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Genzyme, a Sanofi Company American Association for Cancer Research	Phase 2
NCT04177004	Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant	Allogeneic Hematopoietic Stem Cell Transplant Recipient Hematopoietic and Lymphoid Cell Neoplasm	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Etoposide Radiation: Fractionated Stereotactic Radiation Therapy Drug: Goat Milk Biological: Palifermin Drug: Sirolimus Drug: Tacrolimus	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04150692	Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma	Multiple Myeloma	Biological: Daratumumab Procedure: Blood for research assessments Procedure: Bone marrow for research assessments	Washington University School of Medicine Janssen, LP	Phase 2
NCT04150640	P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric	Esophageal Adenocarcinoma Gastric Adenocarcinoma	Drug: Nal-IRI Drug: Oxaliplatin Drug: 5-FU Drug: Trastuzumab	University of Wisconsin, Madison Ipsen	Phase 2
NCT04149275	Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma	Carcinosarcoma of Ovary Carcinosarcoma of Uterus Carcinosarcoma of Vagina	Drug: Cabozantinib Drug: Ipilimumab Drug: Nivolumab	University of Alabama at Birmingham	Phase 2
NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	Human Papillomavirus Type 16 Cervical Intraepithelial Neoplasia Grade III Cervical Intraepithelial Neoplasia, Grade III	Drug: pNGVL4aCRTE6E7L2	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI)	Phase 1
NCT04077021	First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer	Castration-Resistant Prostatic Cancer	Drug: CCW702	Calibr, a division of Scripps Research	Phase 1
NCT04059757	Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD	Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)	Biological: Fecal Microbiota Transplantation (FMT)	Leland Metheny Case Comprehensive Cancer Center	Phase 2
NCT04056910	Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors	Advanced Solid Tumor IDH1 Mutation Glioma	Drug: ivosidenib and nivolumab	Jason J. Luke, MD Agiros Pharmaceuticals, Inc. Bristol-Myers Squibb University of Pittsburgh	Phase 2
NCT03991741	Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors	Metastatic Melanoma Locally Advanced Refractory/Recurrent Melanoma Metastatic Head and Neck Cancer Locally Advanced Refractory/Recurrent Head and Neck Cancer	Biological: Autologous Tumor Infiltrating Lymphocytes Biological: High-Dose Interleukin 2	Gregory Daniels Immunotherapy Foundation University of California, San Diego	Phase 1

# 해외 바이오의약품 임상 현황 (2020.06.29~2020.07.05)

한국바이오의약품협회, 2020.7.7.  
출처: ClinicalTrials.gov

NCT03969446	Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory	Acute Myeloid Leukemia High Risk Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent High Risk Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory High Risk Myelodysplastic Syndrome Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia	Drug: Decitabine Biological: Pembrolizumab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2
NCT03939585	Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT	Allogeneic Stem Cell Transplant Candidate Acute Myeloid/Lymphoblastic Leukemia Myelodysplastic Syndrome Myeloproliferative Neoplasms Lymphoproliferative Disorders	Biological: Cellular therapy product	Case Comprehensive Cancer Center	Phase 1
NCT03929029	Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma	Melanoma	Drug: Nivolumab Biological: NeoVax plus Montanide Drug: Ipilimumab	Dana-Farber Cancer Institute National Cancer Institute (NCI)	Phase 1
NCT03872505	Pre-operative Non-Anthracycline Chemotherapy, Durvalumab +/- Radiation Therapy in Triple Negative Breast Cancer	Breast Cancer Triple Negative Breast Cancer	Drug: Durvalumab Radiation: Radiation Therapy Drug: Carboplatin Drug: Paclitaxel	Cedars-Sinai Medical Center AstraZeneca	Phase 2
NCT03688178	DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varilumab	Glioblastoma	Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs Drug: Temozolomide Biological: Varilumab Biological: Td Biological: 111In-labeled DCs Biological: Unpulsed DCs	Gary Archer Ph.D. Celldex Therapeutics Duke University	Phase 2
NCT03598816	Polymune (Durvalumab (MEDI4736) and Tremelimumab) & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma	Renal Cell Carcinoma	Drug: Durvalumab Drug: Tremelimumab Device: TDS-IM v1.0 System Biological: Neoantigen DNA Vaccine Procedure: Research blood draw	Washington University School of Medicine MedImmune LLC	Phase 2
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Urologic Diseases Male Urogenital Diseases Penile Diseases Corpus Callosum Malformation Corpora Cavernosa; Inflammation Trauma Injury	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT03258658	Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures	Urologic Diseases Male Urogenital Diseases Urethral Stricture Urethral Injury	Biological: Autologous Engineered Urethral Construct	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT04448834	Blinicyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphia CD19+ ALL	B-cell Acute Lymphoblastic Leukemia	Drug: Blinatumomab	David Rizzieri, MD Amgen Acrotech Biopharma Duke University	Phase 2
NCT04443348	Pre-op Pembro + Radiation Therapy in Breast Cancer	Triple Negative Breast Cancer Hormone Receptor Positive (HR+), HER2-negative Breast Cancer Biopsy-proven, Positive Lymph Node(s)	Radiation: Radiation Therapy Boost Drug: Pembrolizumab Drug: Paclitaxel Drug: Carboplatin Drug: Cyclophosphamide Drug: Doxorubicin	Alice Ho Merck Sharp & Dohme Corp. Breast Cancer Research Foundation Translational Breast Cancer Research Consortium Massachusetts General Hospital	Phase 2
NCT04406272	VB-111 in Surgically Accessible Recurrent/Progressive GBM	Glioblastoma Recurrent Glioblastoma	Drug: VB11 Procedure: Surgery Other: Placebo Drug: Bevacizumab	Dana-Farber Cancer Institute Vascular Biogenics Ltd. operating as VBL Therapeutics	Phase 2
NCT04294004	KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion	Degenerative Disc Disease Spinal Fusion	Combination Product: TgPlPTH1-34 in fibrin Other: Autologous Bone Graft	Kuros Biosurgery AG Factory CRO Kuros BioSciences BV	Phase 2
NCT04258397	Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease	Chronic Kidney Disease	Drug: Pirfenidone Drug: matching placebo	Veterans Medical Research Foundation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) San Diego Veterans Healthcare System University of California, San Diego University of California, San Francisco	Phase 2
NCT03607955	Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy	Epithelial Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Cancer	Drug: AVB-S6-500 Drug: Paclitaxel Drug: Carboplatin Procedure: Tissue from Diagnostic Laparoscopy Procedure: Tissue from Core biopsy Procedure: Interval Debulking Procedure: Peripheral blood Procedure: Ascites collection	Washington University School of Medicine Aravive, Inc.	Phase 1
NCT03575234	Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer	Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7	Drug: Cyclophosphamide Biological: IRX-2 Biological: Nivolumab Procedure: Surgery	Emory University Bristol-Myers Squibb Brooklyn ImmunoTherapeutics, LLC	Phase 1
NCT04303169	Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C)	Melanoma	Biological: Pembrolizumab Biological: MK-7684 Biological: V937	Merck Sharp & Dohme Corp.	Phase 1  Phase 2
NCT04240704	Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)	Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia	Drug: JBH492	Novartis Pharmaceuticals Novartis	Phase 1
NCT04430894	KRDI in Transplant-Eligible MM	Multiple Myeloma	Drug: Carfilzomib Drug: Isatuximab Drug: Lenalidomide Drug: Dexamethasone	Massachusetts General Hospital Amgen Sanofi	Phase 2

# 해외 바이오의약품 임상 현황 (2020.06.29~2020.07.05)

한국바이오의약품협회, 2020.7.7.  
출처: ClinicalTrials.gov

NCT04413123	Cabozantinib In Combo With NIVO + IPI In Advanced NCCRC	Papillary Renal Cell Carcinoma[Unclassified Renal Cell Carcinoma]Translocation Renal Cell Carcinoma[Chromophobe Renal Cell Carcinoma]Collecting Duct Renal Cell Carcinoma[Medullary Renal Cell Carcinoma]Renal Cell Carcinoma[Unresectable Advanced Renal Cell Carcinoma]Metastatic Ncc Renal Cell Carcinoma	Drug: Cabozantinib[Drug: Nivolumab]Drug: Ipilimumab	Bradley A. McGregor[Bristol-Myers Squibb][Exelixis][Dana-Farber Cancer Institute]	Phase 2
NCT04250636	3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals	Human Immunodeficiency Virus	Drug: 3BNC117-LS[Drug: 10-1074-LS]	Rockefeller University[National Institute of Allergy and Infectious Diseases (NIAID)]Weill Medical College of Cornell University[Perelman School of Medicine University of Pennsylvania]	Phase 1
NCT04098250	Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH	Post-Traumatic Headache	Drug: Erenumab[Other: Placebo]	Mayo Clinic[University of Arizona]Translational Genomics Research Institute[Arizona State University]Phoenix VA Health Care System[United States Department of Defense]Amgen	Phase 2
NCT03979742	Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord With Lithium Carbonate or Placebo Followed by Locomotor Training	Spinal Cord Injuries	Biological: Umbilical Cord Blood Mononuclear Cell[Drug: Lithium Carbonate][Other: Placebo][Other: Locomotor Training]	StemCyte, Inc.[Amarex Clinical Research]	Phase 2
NCT04305041	Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A)	Melanoma	Biological: Pembrolizumab[Biological: MK-1308][Biological: MK-7684][Drug: Lenvatinib]	Merck Sharp & Dohme Corp.	Phase 1  Phase 2
NCT04355767	Convalescent Plasma in Outpatients With COVID-19	COVID-19	Biological: Convalescent Plasma[Biological: Saline]	Stanford University[National Heart, Lung, and Blood Institute (NHLBI)]Strategies to Innovate EmergEncy Care Clinical Trials Network (SIREN) - Network	Phase 3
NCT04334980	Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19	COVID-19	Biological: bacTRL-Spike[Other: Placebo]	Symvivo Corporation	Phase 1
NCT04428476	Open-label Extension of the HOPE-2 Trial	Duchenne Muscular Dystrophy	Biological: CAP-1002	Capricor Inc.	Phase 2
NCT04305054	Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)	Melanoma	Biological: Pembrolizumab[Biological: MK-7684]	Merck Sharp & Dohme Corp.	Phase 1  Phase 2
NCT04452474	Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).	COVID-19	Drug: Olokizumab 64 mg[Drug: Placebo]	R-Pharm[Cromos Pharma, LLC][Covance]	Phase 2  Phase 3
NCT04210375	Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFREF)	Heart Failure With Reduced Ejection Fraction	Drug: JK07[Drug: Matching Placebo]	Salubris Biotherapeutics Inc	Phase 1
NCT04300647	A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer	Cervical Cancer	Drug: Tiragolumab[Drug: Atezolizumab]	Hoffmann-La Roche	Phase 1  Phase 2
NCT04445701	Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma	Multiple Myeloma	Drug: AO-176[Drug: AO-176 + Dex][Drug: AO-176 + Dex + Bort]	Arch Oncology	Phase 1  Phase 2
NCT04219254	A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)	Solid Tumor, Adult	Drug: Pembrolizumab 25 MG/ML(MK-3475)	BiolInvent International AB	Phase 1  Phase 2
NCT04456686	Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis	Osteoarthritis	Drug: LY3016859[Drug: Placebo]	Eli Lilly and Company	Phase 2
NCT04453202	A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults	Healthy	Biological: RSV Vaccine[Other: Placebo]	Janssen Vaccines & Prevention B.V.	Phase 2
NCT04338581	Evaluation of AMG 714 for Vitiligo	Vitiligo	Biological: AMG 714[Biological: Placebo][Procedure: nbUVB phototherapy]	National Institute of Allergy and Infectious Diseases (NIAID)[Amgen]	Phase 2
NCT04221477	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis	Lupus Nephritis	Drug: Obinutuzumab[Drug: MMF][Drug: Prednisone][Drug: Placebo][Drug: Methylprednisolone][Drug: Acetaminophen][Drug: Diphenhydramine]	Hoffmann-La Roche	Phase 3
NCT04176120	Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)	Diabetic Foot Infection Non-healing Wound Non-healing Diabetic Foot Ulcer	Biological: TTAX01[Other: Standard Care]	Tissue Tech Inc.	Phase 3
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo[Drug: BFKB8488A]	Genentech, Inc.	Phase 2
NCT04434196	A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Lymphoma, Non-Hodgkin	Drug: CC-99282[Drug: Obinutuzumab]	Celgene	Phase 1
NCT04385368	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	Drug: Durvalumab + SoC chemotherapy[Other: Placebo + SoC chemotherapy]	AstraZeneca	Phase 3

## 해외 바이오의약품 임상 현황 (2020.06.29~2020.07.05)

한국바이오의약품협회, 2020.7.7.  
출처: ClinicalTrials.gov

NCT04311710	A Study Evaluating the Drug Levels of Ipilimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types	Tumor	Drug: ipilimumab Drug: nivolumab Drug: ENHANZE (rHuPH20)	Bristol-Myers Squibb	Phase 1  Phase 2
NCT04116658	First-in-Human, Phase 1b/2a Trial of a Multipetide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Glioblastoma, Adult	Biological: Multiple dose of EO2401	Enterome Covance	Phase 1  Phase 2

### ○ 영국 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04449939	A Study of Subcutaneous KY1005 in Healthy Volunteers	Immune System Diseases	Drug: KY1005	Kymab Limited	Phase 1
NCT04360941	PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer	Triple Negative Breast Cancer Locally Advanced Breast Cancer Recurrent Breast Cancer Metastatic Breast Cancer ER+ Breast Cancer HER2-positive Breast Cancer	Drug: Palbociclib Drug: Avelumab	Royal Marsden NHS Foundation Trust Pfizer Breast Cancer Now	Phase 1
NCT04389229	OVSTAR TIL Trial (Ovarian Cancer Co-Stimulatory Antigen Receptor TIL Trial)	Ovarian Cancer Metastatic	Drug: cyclophosphamide Drug: fludarabine Drug: IL-2 (Proleukin) Genetic: Unmodified Tumour Infiltrating Lymphocytes (UTIL-01) Genetic: Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)	Immetacyle Ltd	Phase 1  Phase 2
NCT04300647	A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer	Cervical Cancer	Drug: Tiragolumab Drug: Atezolizumab	Hoffmann-La Roche	Phase 1  Phase 2
NCT04221477	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis	Lupus Nephritis	Drug: Obinutuzumab Drug: MMF Drug: Prednisone Drug: Placebo Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3

### ○ 프랑스 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04432389	Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture	Tibial Fracture	Biological: ALLOB Other: placebo	Bone Therapeutics S.A ICON plc	Phase 2
NCT04300647	A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer	Cervical Cancer	Drug: Tiragolumab Drug: Atezolizumab	Hoffmann-La Roche	Phase 1  Phase 2
NCT04311710	A Study Evaluating the Drug Levels of Ipilimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types	Tumor	Drug: ipilimumab Drug: nivolumab Drug: ENHANZE (rHuPH20)	Bristol-Myers Squibb	Phase 1  Phase 2
NCT04357873	Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations	Squamous Cell Lung Cancer Vulvar Cancer Penile Cancer Cervix Cancer Head and Neck Squamous Cell Carcinoma Anal Cancer	Drug: pembrolizumab; vorinostat	UNICANCER Merck Sharp & Dohme Corp. Fondation ARC	Phase 2
NCT04239196	Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA	Giant Cell Arteritis Optic Ischaemic Neuropathy	Drug: tocilizumab and IV steroids combination Other: IV steroids combination alone	Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Roche Chugai	Phase 2
NCT04221477	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis	Lupus Nephritis	Drug: Obinutuzumab Drug: MMF Drug: Prednisone Drug: Placebo Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo Drug: BFKB8488A	Genentech, Inc.	Phase 2
NCT04116658	First-in-Human, Phase 1b/2a Trial of a Multipetide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Glioblastoma, Adult	Biological: Multiple dose of EO2401	Enterome Covance	Phase 1  Phase 2

### ○ 독일 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04116658	First-in-Human, Phase 1b/2a Trial of a Multipetide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Glioblastoma, Adult	Biological: Multiple dose of EO2401	Enterome Covance	Phase 1  Phase 2
NCT04309409	Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma	Malignant Melanoma Stage II	Drug: Nivolumab	University Hospital, Essen	Phase 3
NCT04274426	Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer	Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma	Drug: Carboplatin Drug: Pegylated liposomal doxorubicin (PLD) Drug: Gemcitabine Drug: Paclitaxel Drug: Mirvetuximab Soravtansine	AGO Research GmbH	Phase 2
NCT04221477	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis	Lupus Nephritis	Drug: Obinutuzumab Drug: MMF Drug: Prednisone Drug: Placebo Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3
NCT04385368	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	Drug: Durvalumab + SoC chemotherapy Other: Placebo + SoC chemotherapy	AstraZeneca	Phase 3

## 해외 바이오의약품 임상 현황 (2020.06.29~2020.07.05)

한국바이오의약품협회, 2020.7.7.  
출처: ClinicalTrials.gov

○ 중국 20건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04446091	A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)	Colorectal Cancer	Drug: Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.) Drug: Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan	Zhejiang Cancer Hospital	Phase 1  Phase 2
NCT04444167	A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma	Hepatocellular Carcinoma	Biological: AK104 Drug: Lenvatinib	Akeso Akeso Pharmaceuticals, Inc.	Phase 1  Phase 2
NCT04435652	A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.	Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Drug: QL1604 Drug: Nab-paclitaxel Drug: Paclitaxel	Qilu Pharmaceutical Co., Ltd.	Phase 2  Phase 3
NCT04205435	β-globin Restored Autologous HSC in β-thalassemia Major Patients	β-thalassemia Major	Biological: β-globin restored autologous HSC	Shanghai Bioray Laboratory Inc PLA 923 Hospital	Phase 1  Phase 2
NCT04448379	Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Drug: JMT101	Shanghai JMT-Bio Inc CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 1
NCT04437212	Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer	Advanced Esophageal Squamous Cell Cancer	Drug: Toripalimab	RenJi Hospital	Phase 2
NCT04421352	Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients	Relapsed Small Cell Lung Cancer	Drug: CS1001	CStone Pharmaceuticals	Phase 1
NCT04411550	Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects	Healthy Male Volunteers	Drug: HLX11 Drug: CN-Perjeta(Pertuzumab) Drug: EU-Perjeta(Pertuzumab) Drug: US-Perjeta(Pertuzumab)	Shanghai Henlius Biotech	Phase 1
NCT04411537	The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer	Locally Advanced Rectal Cancer	Drug: PD-1 antibody Drug: Capecitabine Drug: Irinotecan Radiation: Neoadjuvant Radiotherapy	Fudan University	Phase 2
NCT04411524	The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer	Locally Advanced Rectal Cancer	Drug: PD-1 antibody Drug: Capecitabine Drug: Irinotecan Radiation: Neoadjuvant Radiotherapy	Fudan University	Phase 2
NCT04408261	Buqitongluo Granule for Qi Deficiency and Blood Stasis Syndrome	Stroke, Ischemic Coronary Artery Disease Angina Pectoris, Stable Diabetic Peripheral Neuropathy	Drug: Buqitongluo Granule Drug: Buqitongluo Granule Placebo Other: Standard care	Dongzhimen Hospital, Beijing The Affiliated Hospital of Changchun University of Chinese Medicine The Affiliated Hospital of Shandong University of Chinese Medicine The Affiliated Hospital of Chengdu University of Chinese Medicine The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine Hunan Academy of Traditional Chinese Medicine Affiliated Hospital The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine Shaanxi Buchang Pharmaceuticals Co., Ltd. Beijing Chuanglikechuang Medical Technology Development Co., Ltd. Shanghai Youningwei Biotechnology Co., Ltd. Wuhan Zhizhi Medical Technology Co., Ltd.	Phase 2
NCT04235959	A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus	Diabetes Mellitus, Type 2	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 1
NCT04211168	Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers	Advanced Biliary Tract Cancer	Drug: Toripalimab plus Lenvatinib	Peking Union Medical College Hospital Shanghai Junshi Biosciences Co., LTD	Phase 2
NCT04433221	Combination Immunotherapy Targeting Sarcomas	Sarcoma Osteoid Sarcoma Ewing Sarcoma	Biological: Multiple sarcoma-specific CAR-T cells and sarcoma vaccines	Shenzhen Geno-Immune Medical Institute The Seventh Affiliated Hospital, Sun Yat-Sen University Shenzhen Children's Hospital	Phase 1  Phase 2
NCT04337658	Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer	HER2-positive Breast Cancer	Drug: Pertuzumab Drug: Trastuzumab Drug: Fulvestrant Drug: Capecitabine	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 3
NCT04357522	Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers	Pneumonia, Pneumococcal	Biological: 15-Valent Pneumococcal Conjugate Vaccine Biological: 13-Valent Pneumococcal Conjugate Vaccine	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Phase 3
NCT04453826	Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma Chemotherapy Radiotherapy PD-1 Therapy	Drug: Camrelizumab plus chemo-radiotherapy Drug: Chemo-radiotherapy alone	Sun Yat-sen University Affiliated Cancer Hospital & Institute of Guangzhou Medical University Zhongshan People's Hospital, Guangdong, China Yuebei People's Hospital Wuzhou Red Cross Hospital Fifth Affiliated Hospital, Sun Yat-Sen University	Phase 3

## 해외 바이오의약품 임상 현황 (2020.06.29~2020.07.05)

한국바이오의약품협회, 2020.7.7.  
출처: ClinicalTrials.gov

NCT04453813	Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma	Recurrent Nasopharyngeal Carcinoma Chemotherapy Radiotherapy PD-1 Treatment	Drug: Toripalimab plus concurrent chemo-radiotherapy Drug: Concurrent chemo-radiotherapy	Sun Yat-sen University Affiliated Cancer Hospital & Institute of Guangzhou Medical University Zhongshan People's Hospital, Guangdong, China Yuebei People's Hospital Wuzhou Red Cross Hospital Fifth Affiliated Hospital, Sun Yat-Sen University	Phase 3
NCT04426825	A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Atezolizumab Drug: Bevacizumab	Hoffmann-La Roche	Phase 2
NCT04236141	A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).	Diffuse, Large B-Cell, Lymphoma	Drug: Polatuzumab Vedotin Drug: Bendamustine Drug: Rituximab Drug: Placebo	Hoffmann-La Roche	Phase 3

### ○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04240704	Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)	Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia	Drug: JBH492	Novartis Pharmaceuticals Novartis	Phase 1
NCT04317066	A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)	Lymphoma, B-Cell	Drug: Pembrolizumab	Merck Sharp & Dohme Corp.	Phase 1
NCT04385368	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	Drug: Durvalumab + SoC chemotherapy Other: Placebo + SoC chemotherapy	AstraZeneca	Phase 3